EUVIMEDEUVIMED entdecken
VergleichsstudieMetaanalyseSystematische Übersicht

Glecaprevir/Pibrentasvir Versus Sofosbuvir/Velpatasvir for Hepatitis C Virus Genotype 6: A Systematic Review and Meta‐Analysis

Duong Hoang Huy Le, Dinh Chuong Nguyen, Sitthichai Kanokudom, Jiratchaya Puenpa, Pornjarim Nilyanimit, Anh Ngoc Tran, Sittisak Honsawek, Yong Poovorawan

Reviews in Medical Virology · 2025

DOI: 10.1002/rmv.70074 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Reviews in Medical Virology, 2025. Verfasst von Duong Hoang Huy Le und 7 weiteren Autor:innen. Beteiligte Einrichtung: Center of Excellence in Clinical Virology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. Hauptthemen laut MEDLINE: Antiviral Agents, Benzimidazoles, Carbamates, Hepacivirus. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 72 Literaturangaben. Gefördert von: Graduate Scholarship Program for ASEAN or Non-ASEAN countries, The MK restaurant Group Aunt Thongkum Foundation, The BJC Big C Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The Hepatitis C virus genotype 6 (HCV GT6), found in mainland Southeast Asia and Southern China, poses treatment challenges due to its genetic diversity. This systematic review and meta‐analysis compared the efficacy and safety of two pan‐genotypic direct‐acting antiviral regimens, glecaprevir/pibrentasvir (GLE/PIB) and sofosbuvir/velpatasvir (SOF/VEL), for treating chronic HCV GT6. We followed PRISMA guidelines and searched PubMed, Embase, and the Cochrane Library for trials and studies. The primary outcome was the 12‐week sustained virologic response (SVR 12 ). We performed single‐arm meta‐analyses of proportions using methods robust for proportion data with prevalent boundary values and calculated the pooled risk difference (RD) for head‐to‐head comparisons. Twenty‐seven studies published between 2015 and 2025, comprising 1522 patients (451 GLE/PIB and 1071 SOF/VEL), were included. The pooled single‐arm SVR 12 rate for SOF/VEL was a highly consistent 99.0% (95% Confidence Interval (CI): 98.2%–99.4%). The initial pooled rate for GLE/PIB was 95.6% (95% CI: 93.2%–97.1%) with significant heterogeneity; however, a sensitivity analysis removing outlier studies yielded a rate of 99.2% (95% CI: 97.2%–99.8%) with no heterogeneity. Direct comparison across two studies found no significant difference in efficacy (pooled RD: 0.01, 95% CI: −0.01 to 0.02). Both regimens were exceptionally well‐tolerated, with treatment discontinuation rates near zero. GLE/PIB and SOF/VEL are clinically equivalent to treating HCV GT6, achieving near‐universal cure rates with excellent safety profiles. Regimen selection should consider practical factors such as GLE/PIB's shorter 8‐week duration, comorbidities like cirrhosis, drug interaction profiles, and local cost‐effectiveness, rather than minor efficacy differences.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsBenzimidazolesCarbamatesHepacivirusHepatitis C, ChronicHeterocyclic Compounds, 4 or More RingsQuinoxalinesSofosbuvirSulfonamidesHumansAminoisobutyric AcidsDrug CombinationsGenotypeLeucineProlinePyrrolidinesSustained Virologic ResponseTreatment OutcomeBenzopyransCyclopropanesLactams, Macrocyclic

Stichwörter der Autor:innen

12‐week sustained virologic response (SVR12)glecaprevir/pibrentasvir (GLE/PIB)hepatitis C virus genotype 6 (HCV GT6)pan‐genotypicsofosbuvir/velpatasvir (SOF/VEL)

Substanzen

Aminoisobutyric AcidsAntiviral AgentsBenzimidazolesCarbamatesDrug Combinationsglecaprevirglecaprevir and pibrentasvirHeterocyclic Compounds, 4 or More RingsLeucinepibrentasvir

Autor:innen und Institutionen

  • Center of Excellence in Clinical Virology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
  • Medical Biochemistry & Molecular Biology Department, Fundamental Sciences and Basic Medical Sciences, Pham Ngoc Thach University of Medicine, Ho Chi Minh, Vietnam.
  • Biomedical Research Center, Pham Ngoc Thach University of Medicine, Ho Chi Minh City, Vietnam.
  • Department of Gastroenterology, University Medical Center, Ho Chi Minh City, Vietnam.
  • Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
  • Center of Excellence in Osteoarthritis and Musculoskeleton, Faculty of Medicine, Chulalongkorn University, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand.

Förderung

  • Graduate Scholarship Program for ASEAN or Non-ASEAN countries
  • The MK restaurant Group Aunt Thongkum Foundation
  • The BJC Big C Foundation
  • The Center of Excellence in Clinical Virology at Chulalongkorn University
  • The King Chulalongkorn Memorial Hospital

Zitieren

APA

Le, D. H. H., Nguyen, D. C., Kanokudom, S., Puenpa, J., Nilyanimit, P., Tran, A. N., Honsawek, S., & Poovorawan, Y. (2025). Glecaprevir/Pibrentasvir Versus Sofosbuvir/Velpatasvir for Hepatitis C Virus Genotype 6: A Systematic Review and Meta‐Analysis. Reviews in Medical Virology. https://doi.org/10.1002/rmv.70074

Vancouver

Le DHH, Nguyen DC, Kanokudom S, Puenpa J, Nilyanimit P, Tran AN, et al. Glecaprevir/Pibrentasvir Versus Sofosbuvir/Velpatasvir for Hepatitis C Virus Genotype 6: A Systematic Review and Meta‐Analysis. Reviews in Medical Virology. 2025. doi:10.1002/rmv.70074

BibTeX
@article{Le2025,
  author = {Le, Duong Hoang Huy and Nguyen, Dinh Chuong and Kanokudom, Sitthichai and Puenpa, Jiratchaya and Nilyanimit, Pornjarim and Tran, Anh Ngoc and Honsawek, Sittisak and Poovorawan, Yong},
  title = {Glecaprevir/Pibrentasvir Versus Sofosbuvir/Velpatasvir for Hepatitis C Virus Genotype 6: A Systematic Review and Meta‐Analysis},
  journal = {Reviews in Medical Virology},
  year = {2025},
  doi = {10.1002/rmv.70074}
}
Kostenlos starten →